



Market Announcement

3 November 2020

Icannex Healthcare Limited (ASX: IHL) – Trading Halt

Description

The securities of Icannex Healthcare Limited ('IHL') will be placed in trading halt at the request of IHL, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 5 November 2020 or when the announcement is released to the market.

Issued by

Ivan Tatkovich

Adviser, Listings Compliance (Sydney)

Melissa Kostopoulos
Compliance Advisor, Listings Compliance (Melbourne)
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

By email: melissa.kostopoulos@asx.com.au
tradinghaltsmelbourne@asx.com.au

Dear Melissa,

Trading Halt Request

Pursuant to ASX Listing Rule 17.1 Incannex Healthcare Limited (“**the Company**”) (ASX code: IHL) requests that an immediate trading halt be put on its securities, pending an ASX announcement by the Company regarding the results of its animal trial in the development of IHL-675A - a novel treatment for Acute Respiratory Distress Syndrome (‘ARDS’). The Company has received preliminary data from its most recent study and will have final results available for announcement within the next 24-48 hours.

The Company advises the trading halt is to last until the commencement of trade on Thursday 5th November 2020 or the release of the announcement.

The Company confirms that is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

On behalf of the IHL Board of Directors,



Glenn Fowles
Company Secretary